Pfizer (PFE) Debt to Equity (2009 - 2026)
Pfizer (PFE) reported Debt to Equity of $0.72 for Q1 2026, up 4.39% year-over-year from $0.69 in Q1 2025, and down 4.53% on a QoQ basis from $0.75 in Q4 2025.
Pfizer (PFE) has 18 years of Debt to Equity data on file, last reported at $0.72 in Q1 2026.
- Quarterly Debt to Equity rose 4.39% year-over-year to $0.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.72 (up 4.39% YoY) and the FY2025 annual result came in at $0.75, up 3.7% from the prior year.
- Debt to Equity slipped to $0.72 in Q1 2026 per PFE's latest filing, from $0.75 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.81 in Q4 2023 and bottomed at $0.35 in Q2 2023.
- The 5-year median for Debt to Equity is $0.69 (2025), against an average of $0.63.
- The widest annual swing landed in 2022, when Debt to Equity slumped 64.38%; it then jumped 115.54% in 2023.
- Tracing PFE's Debt to Equity over 5 years: stood at $0.37 in 2022, then jumped by 115.54% to $0.81 in 2023, then decreased by 10.25% to $0.72 in 2024, then rose by 3.7% to $0.75 in 2025, then dropped by 4.53% to $0.72 in 2026.
- Per Business Quant, the three latest PFE Debt to Equity figures stand at $0.72 (Q1 2026), $0.75 (Q4 2025), and $0.66 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.22 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 1.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 0.72 |
| Dec 31, 2025 | 0.75 |
| Sep 28, 2025 | 0.66 |
| Jun 29, 2025 | 0.69 |
| Mar 30, 2025 | 0.69 |
| Dec 31, 2024 | 0.72 |
| Sep 29, 2024 | 0.73 |
| Jun 30, 2024 | 0.79 |
| Mar 31, 2024 | 0.75 |
| Dec 31, 2023 | 0.81 |
| Oct 1, 2023 | 0.65 |
| Jul 2, 2023 | 0.66 |
| Apr 2, 2023 | 0.35 |
| Dec 31, 2022 | 0.37 |
| Oct 2, 2022 | 0.39 |
| Jul 3, 2022 | 0.46 |
| Apr 3, 2022 | 0.44 |
| Dec 31, 2021 | 0.49 |
| Oct 3, 2021 | 1.11 |
| Jul 4, 2021 | 0.56 |
| Apr 4, 2021 | 0.58 |
| Dec 31, 2020 | 0.63 |
| Sep 27, 2020 | 1.85 |
| Jun 28, 2020 | 0.99 |
| Mar 29, 2020 | 0.80 |
| Dec 31, 2019 | 0.82 |
| Sep 29, 2019 | 1.49 |
| Jun 30, 2019 | 0.78 |
| Mar 31, 2019 | 0.76 |
| Dec 31, 2018 | 0.65 |
| Sep 30, 2018 | 0.57 |
| Jul 1, 2018 | 0.58 |
| Apr 1, 2018 | 0.58 |
| Dec 31, 2017 | 0.61 |
| Oct 1, 2017 | 0.72 |
| Jul 2, 2017 | 0.74 |
| Apr 2, 2017 | 0.75 |
| Dec 31, 2016 | 0.70 |
| Oct 2, 2016 | 0.69 |
| Jul 3, 2016 | 0.70 |
| Apr 3, 2016 | 0.62 |
| Dec 31, 2015 | 0.60 |
| Sep 27, 2015 | 0.58 |
| Jun 28, 2015 | 0.53 |
| Mar 29, 2015 | 0.53 |
| Dec 31, 2014 | 0.51 |
| Sep 28, 2014 | 0.47 |
| Jun 29, 2014 | 0.49 |
| Mar 30, 2014 | 0.48 |
| Dec 31, 2013 | 0.48 |
| Sep 29, 2013 | 0.47 |
| Jun 30, 2013 | 0.47 |
| Mar 31, 2013 | 0.49 |
| Dec 31, 2012 | 0.46 |
| Sep 30, 2012 | 0.48 |
| Jul 1, 2012 | 0.48 |
| Apr 1, 2012 | 0.47 |
| Dec 31, 2011 | 0.47 |
| Oct 2, 2011 | 0.46 |
| Jul 3, 2011 | 0.47 |
| Apr 3, 2011 | 0.46 |
| Dec 31, 2010 | 0.50 |
| Oct 3, 2010 | 0.50 |
| Jul 4, 2010 | 0.50 |
| Apr 4, 2010 | 0.51 |
| Dec 31, 2009 | 0.48 |
| Sep 27, 2009 | 0.59 |
| Jun 28, 2009 | 0.63 |